Frontlight ResearchEarly access
Not yet recruitingPhase 2
Testing if dexmedetomidine, a sedative drug, helps to protect the brain after sudden cardiac arrest outside a hospital
Key facts
- Who runs it
- Medical University Of Vienna
- Where
- Austria1 site in 1 countryChoose a country to see its sites
- Trial code
- EU 2026-527007-21-00
- ISRCTN69111582
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 1 Nov 2028
- Type of study
- Interventional
- Record updated
- 9 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Adult patients ≥18 years of age experiencing out-of-hospital cardiac arrest
- Sustained circulation (defined as ROSC or successful eCPR flow lasting for at least 20 minutes) within 90 minutes of suspected collapse
- Comatose (Glasgow Coma Scale <8) on admission or suspected in patients receiving sedatives
- Start of the trial drug is possible within 2 hours of hospital admission
- Subjected to temperature control
- Combined no-flow and low-flow time of ≥10 minutes
Who cannot take part
- Requirement of acute surgery at screening
- Known limitations to intensive care therapy and “Do Not Resuscitate” or “Allow Natural Death” orders
- Expected death within 72 hours or known medical condition limiting expected survival to < 3 months
- Known allergies or intolerances against any of the substances used in the trial
- Known diseases that may interfere with biomarkers indicative of neurologic injury (e.g., cancer, inflammation, acute bleeding, stroke or infection of the central nervous system) at the discretion of the investigator
- Unwitnessed cardiac arrest unless the no-flow time can safely be assumed to be <10minutes
- Pregnancy or breastfeeding
- Advanced directive of patient to decline resuscitation, intensive care measures, or participation in a clinical trial according to the local legal requirements of participating trial sites
- Known pre-arrest CPC of 3 or 4
- Time to sustained circulation > 90 minutes
- No-flow time >10 minutes
- Unmanageable hemodynamic and respiratory instability albeit the use of vasopressors and/or mechanical circulatory support – at the discretion of the treating physicians
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate the effects of dexmedetomidine in patients after out-of-hospital cardiac arrest in comparison to placebo, as measured by the ranked composite of death before 72h and of neuron-specific enolase (NSE) 72h after cardiac arrest
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- DEXmedetomidine to Improve Neurologic Injury of patients after out-of-hospital cardiac arrest – a phase II randomized, double blind, placebo-controlled, parallel group trial
- Record updated
- 9 November 2026